By the age of four months, the retinas of mice carrying a mutation in the gene encoding PDE6? (left) are thin and lack rod photoreceptors (red). But mice who have had this mutation corrected through the PESpRY system (right) have much thicker retinas containing numerous rod cells.
CREDIT: Qin et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20220776
Researchers in China have successfully restored the vision of mice with retinitis pigmentosa, one of the major causes of blindness in humans. The study, to be published March 17 in the Journal of Experimental Medicine, uses a new, highly versatile form of CRISPR-based genome editing with the potential to correct a wide variety of disease-causing genetic mutations.
Researchers have previously used genome editing to restore the vision of mice with genetic diseases, such as Leber congenital amaurosis, that affect the retinal pigment epithelium, a layer of non-neuronal cells in the eye that supports the light-sensing rod and cone photoreceptor cells. However, most inherited forms of blindness, including retinitis pigmentosa, are caused by genetic defects in the neural photoreceptors themselves.
“The ability to edit the genome of neural retinal cells, particularly unhealthy or dying photoreceptors, would provide much more convincing evidence for the potential applications of these genome-editing tools in treating diseases such as retinitis pigmentosa,” says Kai Yao, a professor at the Wuhan University of Science and Technology.
Retinitis pigmentosa can be caused by mutations in over 100 different genes and is estimated to impair the vision of 1 in 4,000 people. It begins with the dysfunction and death of dim light-sensing rod cells, before spreading to the cone cells required for color vision, eventually leading to severe, irreversible vision loss.
Yao and colleagues attempted to rescue the vision of mice with retinitis pigmentosa caused by a mutation in the gene encoding a critical enzyme called PDE6?. To do this, Yao’s team developed a new, more versatile CRISPR system called PESpRY, which can be programmed to correct many different types of genetic mutation, regardless of where they occur within the genome.
When programmed to target the mutant PDE6? gene, the PESpRY system was able to efficiently correct the mutation and restore the enzyme’s activity in the retinas of mice. This prevented the death of rod and cone photoreceptors and restored their normal electrical responses to light.
Yao and colleagues performed a variety of behavioral tests to confirm that the gene-edited mice retained their vision even into old age. For example, the animals were able to find their way out of a visually guided water maze almost as well as normal, healthy mice and showed typical head movements in response to visual stimuli.
Yao cautions that much work still needs to be done to establish both the safety and efficacy of the PESpRY system in humans. “However, our study provides substantial evidence for the in vivo applicability of this new genome-editing strategy and its potential in diverse research and therapeutic contexts, in particular for inherited retinal diseases such as retinitis pigmentosa,” Yao says.
Original Article: New gene-editing technique reverses vision loss in mice
More from: Wuhan University of Science and Technology
The Latest Updates from Bing News
Go deeper with Bing News on:
- Thomas Coysh, the 'Blind Skiwi' with an Olympic dream
"When I’m out on the mountain, it’s me and my guides, skiing like anyone else does," says blind skier Thomas Coysh.
- Retinitis Pigmentosa News, Research and Latest Updates
Keep abreast with the latest news related to Retinitis Pigmentosa there are 13 news items on Retinitis Pigmentosa that covers updates, breakthroughs and in-depth reports. We provide you with a ...
- Retinitis Pigmentosa: Genetics and Gene-Based Approaches to Therapy
Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders; and over 50 genes underlying ...
- Spanish ophthalmologist visits Holguin Retinitis Pigmentosa Center
Sergio Bonafonte Royo, specialist in Ophthalmology and director of the Bonafonte Ophthalmological Center of Spain, visited this Wednesday the Provincial Center of Retinitis Pigmentosa “Orfilio Pelaez” ...
- Disease Focus: Retinitis Pigmentosa
Retinitis pigmentosa is a blinding eye disease that affects approximately 150,000 individuals in the US and 1.5 million people around the world. It is caused by the destruction of light-sensing cells ...
Go deeper with Bing News on:
- Nano (XNO) Price Prediction 2023, 2024, 2025–2030
According to our Nano price prediction, XNO is forecasted to trade within a price range of $ 0.724169 and $ 0.726660 this week. Nano will increase by 0.34% and reach $ 0.726660 by Dec 03, 2023 if it ...
- 500m from Nano land, Japanese firm sows Singur turnaround seed
A Japanese firm, Singur Vegetables, has started procuring fresh produce from Singur's fields to sell in Kolkata. This foreign investment in Singur is ...
- North Carolina goes all in on EV batteries. Will it pay off or flop?
North Carolina is winning thousands of jobs linked to batteries for electric vehicles. But whether they fully materialize will depend on consumer demand.
- Nano One Materials Corp NANO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
- Nano-X Imaging GAAP EPS of -$0.37 misses by $0.07, revenue of $2.48M misses by $0.78M
Q3 GAAP EPS of -$0.37 misses by $0.07. Revenue of $2.48M (+1.6% Y/Y) misses by $0.78M. Non-GAAP net loss attributable to ordinary shares for the reported period was $9.4 million, as compared to $8.1 ...